After demonstrating that genetically and pharmacologically perturbing BACE1 expression and activity, respectively, altered the growth and invasiveness of NSCLC and LBM lines in vitro, we wanted to assess whether we could limit the spread of BACE1-expressing disseminated LUAD cells to the brain by targeting BACE1 activity with MK-8931. Here, BACE1 is linked to non-small cell lung carcinoma.